These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 12691141)

  • 1. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
    Silver RT; Peterson BL; Szatrowski TP; Powell BL; Stock W; Carroll AJ; Bloomfield CD; Schiffer CA; Larson RA
    Leuk Lymphoma; 2003 Jan; 44(1):39-48. PubMed ID: 12691141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
    Giles FJ; Kantarjian H; O'Brien S; Rios MB; Cortes J; Beran M; Koller C; Keating M; Talpaz M
    Leuk Lymphoma; 2001 Apr; 41(3-4):309-19. PubMed ID: 11378543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
    Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
    Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia.
    Millot F; Guilhot J; Nelken B; Leblanc T; Leverger G; Bernard F; Gandemer V; Béhard C; Berger C; Cornu G; Duchène S; Guilhot F
    Pediatr Blood Cancer; 2006 Oct; 47(5):555-9. PubMed ID: 16317737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
    Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
    Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
    O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
    Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
    Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
    Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
    Guilhot F; Chastang C; Michallet M; Guerci A; Harousseau JL; Maloisel F; Bouabdallah R; Guyotat D; Cheron N; Nicolini F; Abgrall JF; Tanzer J
    N Engl J Med; 1997 Jul; 337(4):223-9. PubMed ID: 9227927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
    Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
    N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
    Maloisel F; Guerci A; Guyotat D; Ifrah N; Michallet M; Reiffers J; Tertain G; Blanc M; Bauduer F; Brière J; Abgrall JF; Pegourie-Bandelier B; Solary E; Cambier N; Coso D; Vilque JP; Delain M; Harousseau JL; Rousselot P; Belhadj K; Morice P; Attal J; Chabin M; Chastang C; Guilhot J; Guilhot F;
    Leukemia; 2002 Apr; 16(4):573-80. PubMed ID: 11960335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia.
    Arthur CK; Ma DD
    Acta Haematol; 1993; 89 Suppl 1():15-21. PubMed ID: 8475667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.
    Mollee P; Arthur C; Hughes T; Januszewicz H; Grigg A; Bradstock K; Wolf M; Gibson J; Schwarer AP; Spencer A; Browett P; Hawkins T; Seldon M; Herrmann R; Watson A; Seymour JF; Martin N; Shina S; Low C; Wright S; Rodwell R; Coulston J; Morton J; Blacklock H; Taylor D; Taylor KM
    Ann Oncol; 2004 Dec; 15(12):1810-5. PubMed ID: 15550587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia.
    Lindauer M; Domkin D; Döhner H; Kolb HJ; Neubauer A; Huhn D; Kreiter H; Koch B; Huber C; Aulitzky W; Fischer T
    Br J Haematol; 1999 Sep; 106(4):1013-9. PubMed ID: 10520005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The 6M 12M trial--study of the effectivess and tolerance of treatment in chronic myeloid leukaemia with a combination of interferon alfa and cytarabine].
    Tóthová E; Fricová M; Stecová N; Svorcová E; Guman T; Rraffac S; Kafková A; Hlebasková M
    Vnitr Lek; 2000 Jul; 46(7):391-4. PubMed ID: 15635799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.
    Millot F; Brice P; Philippe N; Thyss A; Demeoq F; Wetterwald M; Boccara JF; Vilque JP; Guyotat D; Guilhot J; Guilhot F
    J Pediatr Hematol Oncol; 2002 Jan; 24(1):18-22. PubMed ID: 11902732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
    Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
    J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.
    Hensley ML; Peterson B; Silver RT; Larson RA; Schiffer CA; Szatrowski TP
    J Clin Oncol; 2000 Mar; 18(6):1301-8. PubMed ID: 10715301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.